2022 Revenues ($USD) : $464,479,000
2022 R&D spend : $49,621,000
2022 Number of Employees : 1,087
Fiscal Year End : 12/31/2021
Company CEO : Jon Serbousek, president and CEO

Orthofix's two strategic business units — Orthofix Spine and Orthofix Orthopedics — develop, make and distribute product lines in more than 60 countries. In May, Orthofix said it received FDA premarket approval (PMA) for its AccelStim bone healing therapy device. In July, the company announced a licensing partnership with LimaCorporate to combine the limb-lengthening technology of Orthofix’s Fitbone intramedullary nail system with LimaCorporate’s proprietary, patient-specific, 3D-printed pelvic fixation device. The company most recently launched its Virtuos Lyograft autograft substitute and marked the first clinical use. –DK and CN